Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders

Julien Matricon, Andrea Giuffrida

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The endocannabinoid system timely orchestrates a variety of cerebral physiological processes by modulating brain neurotransmitters, and in particular the dopamine system. Both endocannabinoid and dopamine receptors are highly abundant and often coexpressed in the basal ganglia and mesolimbic pathways, where they regulate motor functions and motivational aspects of behavior. Understanding the interrelationship between these two systems is crucial to gain new insight on the pathophysiology of brain disorders characterized by a dysregulation of dopamine, such as Parkinson's disease and schizophrenia. This review aims at: (1) presenting the complex functional interactions between these two neurotransmitter systems at the anatomical, pharmacological, cellular and electrophysiological levels, and (2) addressing the contribution of disturbances of cannabinoid-dopamine interactions to neurodegenerative and psychiatric disorders.

Original languageEnglish (US)
Title of host publicationEndocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders
PublisherSpringer New York
Pages73-101
Number of pages29
ISBN (Print)9781461479406, 1461479398, 9781461479390
DOIs
StatePublished - Nov 1 2013

Fingerprint

Cannabinoids
Neurodegenerative Diseases
Dopamine
Endocannabinoids
Neurotransmitter Agents
Physiological Phenomena
Efferent Pathways
Dopamine Receptors
Brain Diseases
Basal Ganglia
Parkinson Disease
Psychiatry
Schizophrenia
Pharmacology
Brain

Keywords

  • CB1
  • Dopamine
  • Dyskinesia
  • Endocannabinoid
  • Parkinson's disease
  • Schizophrenia
  • Signaling
  • Social behavior

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Matricon, J., & Giuffrida, A. (2013). Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. In Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders (pp. 73-101). Springer New York. https://doi.org/10.1007/978-1-4614-7940-6_5

Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. / Matricon, Julien; Giuffrida, Andrea.

Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. Springer New York, 2013. p. 73-101.

Research output: Chapter in Book/Report/Conference proceedingChapter

Matricon, J & Giuffrida, A 2013, Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. in Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. Springer New York, pp. 73-101. https://doi.org/10.1007/978-1-4614-7940-6_5
Matricon J, Giuffrida A. Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. In Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. Springer New York. 2013. p. 73-101 https://doi.org/10.1007/978-1-4614-7940-6_5
Matricon, Julien ; Giuffrida, Andrea. / Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders. Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. Springer New York, 2013. pp. 73-101
@inbook{95135b2e7ae6483bb7ff924e76d9132d,
title = "Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders",
abstract = "The endocannabinoid system timely orchestrates a variety of cerebral physiological processes by modulating brain neurotransmitters, and in particular the dopamine system. Both endocannabinoid and dopamine receptors are highly abundant and often coexpressed in the basal ganglia and mesolimbic pathways, where they regulate motor functions and motivational aspects of behavior. Understanding the interrelationship between these two systems is crucial to gain new insight on the pathophysiology of brain disorders characterized by a dysregulation of dopamine, such as Parkinson's disease and schizophrenia. This review aims at: (1) presenting the complex functional interactions between these two neurotransmitter systems at the anatomical, pharmacological, cellular and electrophysiological levels, and (2) addressing the contribution of disturbances of cannabinoid-dopamine interactions to neurodegenerative and psychiatric disorders.",
keywords = "CB1, Dopamine, Dyskinesia, Endocannabinoid, Parkinson's disease, Schizophrenia, Signaling, Social behavior",
author = "Julien Matricon and Andrea Giuffrida",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-7940-6_5",
language = "English (US)",
isbn = "9781461479406",
pages = "73--101",
booktitle = "Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders",
publisher = "Springer New York",

}

TY - CHAP

T1 - Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders

AU - Matricon, Julien

AU - Giuffrida, Andrea

PY - 2013/11/1

Y1 - 2013/11/1

N2 - The endocannabinoid system timely orchestrates a variety of cerebral physiological processes by modulating brain neurotransmitters, and in particular the dopamine system. Both endocannabinoid and dopamine receptors are highly abundant and often coexpressed in the basal ganglia and mesolimbic pathways, where they regulate motor functions and motivational aspects of behavior. Understanding the interrelationship between these two systems is crucial to gain new insight on the pathophysiology of brain disorders characterized by a dysregulation of dopamine, such as Parkinson's disease and schizophrenia. This review aims at: (1) presenting the complex functional interactions between these two neurotransmitter systems at the anatomical, pharmacological, cellular and electrophysiological levels, and (2) addressing the contribution of disturbances of cannabinoid-dopamine interactions to neurodegenerative and psychiatric disorders.

AB - The endocannabinoid system timely orchestrates a variety of cerebral physiological processes by modulating brain neurotransmitters, and in particular the dopamine system. Both endocannabinoid and dopamine receptors are highly abundant and often coexpressed in the basal ganglia and mesolimbic pathways, where they regulate motor functions and motivational aspects of behavior. Understanding the interrelationship between these two systems is crucial to gain new insight on the pathophysiology of brain disorders characterized by a dysregulation of dopamine, such as Parkinson's disease and schizophrenia. This review aims at: (1) presenting the complex functional interactions between these two neurotransmitter systems at the anatomical, pharmacological, cellular and electrophysiological levels, and (2) addressing the contribution of disturbances of cannabinoid-dopamine interactions to neurodegenerative and psychiatric disorders.

KW - CB1

KW - Dopamine

KW - Dyskinesia

KW - Endocannabinoid

KW - Parkinson's disease

KW - Schizophrenia

KW - Signaling

KW - Social behavior

UR - http://www.scopus.com/inward/record.url?scp=84918779942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918779942&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-7940-6_5

DO - 10.1007/978-1-4614-7940-6_5

M3 - Chapter

AN - SCOPUS:84918779942

SN - 9781461479406

SN - 1461479398

SN - 9781461479390

SP - 73

EP - 101

BT - Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders

PB - Springer New York

ER -